Results 51 to 60 of about 11,697,511 (307)

Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity

ESMO Open, 2020
Background With the development of targeted agents, the approach to combination cancer therapy has evolved to focus on identifying ways in which pathway inhibition by one agent may enhance the activity of other agents.
Malcolm Smith, Jared Foster, Boris Freidlin, E L Korn   +3 more
doaj   +1 more source

Referral Practices and Utilisation of Paediatric Oncology Physiotherapy Services in Ghana: A Cross‐Sectional Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Physical rehabilitation is highly recognised in improving the quality of life of cancer survivors through prehabilitation, sequelae management and palliative care, yet its integration into routine care in Ghana has not been characterised, leading to potential gaps in service access.
Dorothy Ekua Adjabu, Philip Junior Nyarko, Precious Madzimbe, Kofi Adesi Kyei, Tawagidu Mohammed, Sandra Banini   +5 more
wiley   +1 more source

Aggressive variants of prostate cancer : are we ready to apply specific treatment right now?

, 2019
Recently, adoption of novel drugs for systemic treatment of metastatic prostate cancer has led to a striking improvement of response rate and survival in both hormone-sensitive and castration-resistant disease.
Ost, P., Surcel, Cristian, Briganti, Alberto, Valerio, M., Mirvald, Cristian, van den Bergh, R., Kretschmer, A., Valerio, Massimo, Tilki, D., Ploussard, Guillaume, Mirvald, C., Kretschmer, Alexander, van den Bergh, Roderick, Surcel, C., Borgmann, Hendrik, de Visschere, P., Tsaur, I., Heidegger, Isabel, Mathieu, R., Briganti, A., Mathieu, Romain, Gandaglia, Giorgio, De Visschere, Pieter, Heidegger, I., Ploussard, G., Gandaglia, G., Tilki, Derya, Tsaur, Igor, Borgmann, H., Ost, Piet, Ost, PietGE380019993036758020004837230000-0002-2203-4848FBC71966-F0ED-11E1-A9DE-61C894A0A6B4, De Visschere, PieterGE32UZGent0019974248088020023092420000-0002-4842-787785878622-C7A5-11E5-9231-2975B5D1D7B1   +31 more
core   +1 more source

Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment.

, 2021
Rational development of targeted therapies has revolutionized metastatic breast cancer outcomes, although resistance to treatment remains a major challenge. Advances in molecular profiling and imaging technologies have provided evidence for the impact of
Pasha, N, Turner, NC
core   +1 more source

Beyond the Document: A Single‐Center Qualitative Study of Survivorship Care Plan Barriers and Opportunities Across Pediatric Oncology Stakeholders

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survivorship care plans (SCPs) summarize cancer treatment and guide risk‐based follow‐up for cancer survivors, yet remain difficult to create, share, and use. Stakeholder perspectives are needed to inform usable approaches.
Molly S. Talman, Emma Fleisher, Megan E. Salwei, Debra Friedman, Laurie Novak   +4 more
wiley   +1 more source

Gemcitabine: Progress in the treatment of pancreatic cancer [PDF]

, 2001
Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor.
Heinemann, Volker
core   +1 more source

Central Nervous System Tumors Among Infants in Canada: A Report From CYP‐C

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) tumors in infants are rare, pose unique clinical challenges, and lack large‐scale evidence‐based data to guide management. This study seeks to describe CNS tumors in Canadian infants and to compare their outcomes with those of older children.
Samuel Sassine, Hallie Coltin, Sylvia Cheng, Lucie Lafay‐Cousin, Vanan Issai Magimairajan, Craig Erker, Stéphanie Vairy, Lynette Bowes, Adam Fleming, Donna Johnston, Sarah McKillop, Roona Sinha, Julie Bennett, Christina Coleman, Laura Wheaton, Shayna Zelcer, Samuele Renzi, Thai Hoa Tran   +17 more
wiley   +1 more source

Long-term effectiveness of adjuvant Goserelin in premenopausal women with early breast cancer [PDF]

, 2009
BACKGROUND: Systematic reviews have found that luteinizing hormone-releasing hormone (LHRH) agonists are effective in treating premenopausal women with early breast cancer.
Fornander, T, S. Forsyth, Johansson, Ulla,, T. Fornander, U. Johansson, Reczko, Krystyna,, B. Nordenskjold, Nordenskjold, Bo, Fornander, Tommy,, K. Reczko, Reczko, Krystyna, Fohlin, H, Hackshaw, Allan, Fornander, Tommy, Fohlin, Helena,, Valentini, Miriam,, H. Fohlin, Sainsbury, R, Fohlin, Helena, Johansson, U, Monson, Kathryn,, Reczko, K, M. Valentini, Forsyth, Sharon, Sainsbury, Richard,, Nicolucci, A, Monson, K, R. Sainsbury, Baum, M, Sainsbury, Richard, Valentini, Miriam, A. Hackshaw, Nordenskjöld, Bo,, Forsyth, Sharon,, M. Baum, A. Nicolucci, Nordenskjold, B, Fornander, T,, K. Monson, Johansson, Ulla, Nicolucci, Antonio,, Baum, Michael,, Baum, Michael, Hackshaw, Allan,, Hackshaw, A, Valentini, M, Monson, Kathryn, Nicolucci, Antonio, Forsyth, S   +48 more
core   +2 more sources

Spontaneously occurring cardiovascular lesions in commonly used laboratory animals

Cardio-Oncology, 2019
The search for new chemical entities which are clinically effective and do not adversely affect the cardiovascular system is an ongoing objective. In vivo studies designed to detect potential drug-induced cardiovascular toxicity typically utilize both ...
Eugene Herman, Sandy Eldridge
doaj   +1 more source

Pediatric Mediastinal Gray Zone Lymphoma With Germline TET2 Heterozygous Variant

Pediatric Blood &Cancer, EarlyView.
Matthew R. Schuelke, Julia Wang, Haley Newman, Evelyn Kurpiewski, Anne Reilly, Susan R. Rheingold, Gerald Wertheim, Moe Takeda, Daniel J. Zheng, Kaitlin Devine   +9 more
wiley   +1 more source